AI Disruption May Benefit Cencora More Than Hims & Hers

Cencora’s adjusted operating income rose 17% year over year, outpacing 4.9% sales growth, with AI-enabled efficiencies and higher prescription volumes cited as potential drivers. The article says COR trades at 17.7x forward GAAP earnings, about 25% below the sector median, and argues for a 12.5% re-rating to $365–$366 per share.

Analysis

The key underwriting question is not whether automated prescribing raises prescription counts, but whether incremental scripts translate into durable distributor earnings. For Cencora, extra volume can be diluted by low per-unit economics, generic-versus-specialty mix, customer bargaining power, and working-capital needs. If AI mainly reduces administrative friction rather than creating net-new treatment demand, the more credible channel is gradual cost productivity—not a step-change in revenue. That benefit may also be competed away through service pricing.

Any volume or efficiency tailwind is unlikely to be unique: McKesson and Cardinal Health could capture similar industry-wide gains, limiting the case for a Cencora-specific premium. The cited regulatory pilots are an early indicator, not proof of broad adoption; implementation, clinical oversight, reimbursement, and prescribing safeguards could slow rollout. Near term, the stock may react to the optimistic narrative, but a sustained re-rating needs confirmation in reported operating income, script throughput, and cash conversion. Over 6–18 months, the structural upside is better if automation lowers operating costs without worsening service levels or requiring material investment. The contrarian risk is that investors capitalize a broad healthcare-AI theme before there is evidence of incremental distributor economics.

Key Decisions for Investors

• Do not underwrite the proposed valuation re-rating on pilot expansion alone. Verify whether Cencora attributes measurable productivity gains or net-new prescription volume to automation in earnings commentary and filings.
• If seeking exposure, consider a staged COR position rather than chasing an AI-driven move; add only if operating-income growth persists and cash conversion remains sound. The thesis weakens if operating income decelerates materially, working-capital use rises faster than earnings, or guidance fails to reflect productivity gains.
• Monitor McKesson and Cardinal Health disclosures for comparable adoption and operating trends. If benefits appear sector-wide, favor relative valuation and execution evidence over treating Cencora as the sole beneficiary.
• Reassess over the next 1–3 months as companies report results and regulatory pilots develop. A delay or narrowing of pilots, weak evidence of prescription growth, or margin pressure from mix and customer pricing would invalidate the near-term catalyst case.